Product category:
Contract research
News Release from: Domainex
Edited by the Laboratorytalk Editorial
Team on 20 July 2007
Successful completion of collaborative
project
Drug discovery company Domainex and biopharmaceutical firm UCB have successfully completed their first collaborative project with the creation of a particularly elusive target protein construct
Domainex used its combinatorial domain hunting technology to identify a soluble and highly-expressed construct of a protein that had been refractory to other methods This construct was then used by UCB to obtain a high-resolution crystal structure of the target protein with a proprietary inhibitor bound to the active site
This article was originally published on Laboratorytalk on 24 Feb 2003 at 8.00am (UK)
Related stories
First spinal study of bone substitute
Study will measure performance of synthetic bone graft substitute in 30 patients undergoing spinal fusion for degenerative disc disease
Mark Bushfield of UCB commented: "The construct provided by Domainex has all the characteristics that we were looking for, and I am sure this would not have been found using any other method.
"We are currently in discussions to agree the next stage of our collaboration".
Eddy Littler, CEO of Domainex, added: "Our technology is unique, proprietary and offers an opportunity to work on targets hitherto unavailable to the pharmaceutical industry.
"We are delighted that our collaboration with UCB has already come to fruition and we look forward to working together on future projects".
• Domainex: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
